Part of Thermo Fisher Scientific
HOME >
VIP RECEPTOR 1 - DISCONTINUED DISCONTINUED ANTIBODIES > VIP RECEPTOR 1 - DISCONTINUED DISCONTINUED POLYCLONAL ANTIBODY OPA1-15073Z
Anti-VIP Receptor 1 - DISCONTINUED DISCONTINUED Polyclonal Antibody
Printable Datasheet
Synonyms:
VIPR1
| Details | |
| Host / Isotype: | Rabbit |
| Class: | Polyclonal |
| Type: | Antibody |
| Species Reactivity: | Human (Hu) |
| Immunogen: | Synthetic peptide (KLH conjugated) to the 3rd cytoplasmic domain. |
| Ordering Information | ||||
| Pierce Anti-VIP Receptor 1 - DISCONTINUED DISCONTINUED Polyclonal Antibody | ||||
| Product Number | Pkg. Size | Price | Purchase | |
| OPA1-15073Z | 25 µg | $0.00 | ||
| Storage: | -20º C, Avoid Freeze/Thaw Cycles |
| Form: | 25 µg Phosphate buffered saline, PH 7.7 containing 0.01% sodium azide. |
| Applications | Dilution |
| Immunohistochemistry (Paraffin) (IHC (P)) | 1:100 |
| Product Specific Information |
| OPA1-15073Z detects VIPR1 from human samples. OPA1-15073Z has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15073Z detects VIPR1 in formalin fixed, paraffin embedded human tissues. The OPA1-15073Z immunogen is a synthetic peptide (KLH conjugated) corresponding to the 3rd cytoplasmic domain. Figure 1 shows a staining of VIPR1 in human adipose cells using OPA1-15073Z. |
| General Information |
| Vasoactive Intestinal Polypeptide Rec. 1 (VIPR1) expression has been documented widely in normal and cancerous tissues, including adipose, adrenal, bladder, blood, brain, breast, colon, ganglion, GI tract, heart, kidney, liver, lung, lymph node, ovary, pancreas, placenta, prostate, skin, and small intestine. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively. |
(This product is for In Vitro experimental use only.)
 |
|||||||||||||
PO
Box 117, Rockford, IL 61105 USA |
 |
 |
